<DOC>
	<DOCNO>NCT00591019</DOCNO>
	<brief_summary>A study effect FDA approve drug Modafinil upon attention problem associate tinnitus . This consider safe drug side effect . Each subject ask participate 3 session last approximately 1 hour cognitive testing recording take . The study involve subject take 2- week supply Modafinil 2- week supply placebo . We hypothesize inattention relate thalamocortical dysrhythmia find tinnitus reduce Modafinil thus improve vigilance .</brief_summary>
	<brief_title>Use Modafinil Treatment Tinnitus</brief_title>
	<detailed_description>Modafinil , drug primarily use treatment narcolepsy , also use treat attention problem find Attention Deficit Hyperactive Disorder ( ADHD ) . This study investigate efficacy Modafinil upon attention deficit find tinnitus patient assess pre-attentional attentional process ( e.g. , amplitude auditory evoked response simple reaction time ) .</detailed_description>
	<mesh_term>Tinnitus</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>The diagnosis tinnitus establish subject exam history perform study physician Ear , Nose Throat ( ENT ) clinic . Subjects age 20 old . Subjects tinnitus symptom severe enough seek medical attention . Subjects see Hearing Balance Center University Arkansas Medical Sciences ( UAMS ) . Subjects audiogram . Signed informed consent . Women childbearing potential must negative pregnancy test screen prescribe study drug . Peripheral neuropathy . Hematologic ( minimal value ) screen Absolute neutrophil count &gt; 1,500 mm^3 Hemoglobin &gt; 8.0 g/dl Platelet count &gt; 100,000 mm^3 DiseaseSpecific Concerns Subjects locally advance breast cancer skin ulceration exclude study due risk worsen ulcer heal difficulty Stage IV breast cancer Inflammatory breast cancer General Medical Concerns Subjects Echo Cardiogram performance status 2 , 3 , 4 eligible study Allergy component treatment regimen Women breast feeding Pregnancy refusal use effective contraception participate study Inability comply study and/or followup procedure Subjects secondary malignancy superficial skin cancer ( squamous cell carcinoma basal cell carcinoma skin ) exclude BevacizumabSpecific Concerns Current , recent ( within 4 week first infusion study ) , plan participation experimental drug study Blood pressure &gt; 150/100 mmHg . Essential hypertension well control anti hypertensive exclusion criterion Unstable angina New York Heart Association ( NYHA ) Grade II great congestive heart failure ( see Appendix D ) History myocardial infarction within 6 month History stroke within 6 month Clinically significant peripheral vascular disease Evidence bleed diathesis coagulopathy Presence central nervous system brain metastasis Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study Minor surgical procedure fine needle aspiration core biopsy within 7 day prior Day 0 Pregnant ( positive pregnancy test ) lactate Urine protein : creatinine ratio &gt; 1.0 screen History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 0 Serious , nonhealing wound , ulcer , bone fracture</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>P50 , Psychomotor Vigilance Test ( PVT ) , Arousal , Reaction Time</keyword>
</DOC>